INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases. The Company is developing a new concept of immunomodulation targeting the amplification loops of the innate immune response with an initial focus on septic shock. With a high mortality rate, a growing incidence and a lack of specific mechanistically targeted treatment, severe sepsis and septic shock is a major public health problem in urgent need of a solution.

The INOTREM scientists and co-founders are international leaders in TREM-1 biology (Triggering Receptor Expressed on Myeloid cells-1) and authors of numerous studies demonstrating the role of TREM-1 in severe sepsis as well as myocardial infarction.